CRB-913 has a brain to plasma ratio fifty times lower than rimonabant and is fifteen times more peripherally restricted than monlunabant. The Company expects to dose the first participant in the ...

The discussion underscored CRB-701's unique linker technology, which may overcome some limitations of existing ADCs. InvestingPro analysis shows the company maintains a strong financial position ...

FORT LEE, N.J.--(BUSINESS WIRE)--CRB Securities LLC (“CRBS”), a SEC-registered broker-dealer and FINRA member, and Best Egg, Inc., a leading financial technology company that drives financial ...

Isolating the process from the room environment is one of the key things that will allow teams to move to the manufacturing of the future.

Data from the clinical study of CRB-701 presented at a significant oncology symposium (ASCO GU) enhances the company's visibility and credibility in the oncology field. Successful dose escalation ...

Citing safety data, the company said CRB-701, a nectin-4 targeting antibody drug conjugate was well tolerated in the Phase 1 trial with majority of treatment emergent adverse events being grade 1 ...